Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Gene marker for identifying benign and malignant cases of lung micro nodules and application of gene marker

A tiny, nodular technology, applied in the field of molecular biology, can solve problems such as false positives, low detection sensitivity, and low diagnostic value, and achieve the effect of promoting early detection, broad application prospects, and non-invasive sampling methods

Active Publication Date: 2018-10-09
SHANGHAI BIOMEDICAL LAB CO LTD
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, it is very difficult to judge the benign and malignant nature of pulmonary micronodules clinically, mainly because the size of micronodules is less than 10mm, and it is difficult to perform biopsy and pathological examination by fine needle aspiration, even if PET- CT examination, the diagnostic value of the results obtained is also very limited
Detection of other serum tumor markers related to lung cancer, such as carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), squamous cell carcinoma antigen (SCC-Ag), cytokeratin 19 fragment, etc. The auxiliary diagnosis of lung cancer has a certain reference value, but it has little diagnostic value for early lung cancer, especially for ultra-early peripheral lung cancer in situ (stage 0) and stage Ia lung cancer
In addition, conventional tumor serum protein markers usually have low detection sensitivity. For example, the detection sensitivity (positive detection rate) of CEA and NSE for advanced lung cancer is generally only about 30%, and the specificity of serum protein markers for lung cancer detection Other benign lesions such as pneumonia can also cause abnormal concentrations of protein markers, resulting in false positive test results

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Gene marker for identifying benign and malignant cases of lung micro nodules and application of gene marker
  • Gene marker for identifying benign and malignant cases of lung micro nodules and application of gene marker
  • Gene marker for identifying benign and malignant cases of lung micro nodules and application of gene marker

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Example 1 Screening of peripheral blood characteristic gene markers of lung cancer

[0027] The screening of lung cancer characteristic genes includes the following steps:

[0028] 1) Collect peripheral blood samples from 40 patients with malignant micronodules diagnosed as lung cancer by surgery and pathological examination, 16 patients with benign micronodules (benign lung lesions), and 28 healthy people without lung lesions. All patients with micronodules were confirmed by CT examination that the size of the nodules was less than or equal to 10mm, and 2-3ml of peripheral blood was collected from each sample.

[0029] 2) The PAXgene Blood RNA Kit extraction kit was used to extract the total RNA of the above samples, the fragment integrity (RIN) of the RNA sample was detected by the AgilentBioanalyzer 2100 bioanalyzer, and the purity of the RNA sample was detected by the Nano1000 micro-volume ultraviolet spectrophotometer. All RNA samples must meet the following quality...

Embodiment 2

[0038] Example 2 Using the screened lung cancer characteristic gene markers to detect micronodular lung cancer

[0039] 1. Method steps:

[0040] 1) Collection of peripheral blood samples of samples to be tested: use BD PAXgeneRNA blood collection tubes from QIAGEN to collect peripheral blood samples from patients;

[0041] 2) Extraction and purification of total RNA in the peripheral blood sample of the sample to be tested: use QIAGEN's PAXgeneBloodRNAKit to extract and purify the total RNA in the peripheral blood, and use the Agilent BioAnalyzer 2100 microelectrophoresis analyzer to identify the integrity and yield of the extracted total RNA fragments. Use Nano1000 micro-volume ultraviolet spectrophotometer to detect the purity of RNA samples;

[0042] 3) Reverse transcription reaction: use Life Techonolgy's High-Capacity cDNA ReverseTranscription kit reverse transcription kit, use total RNA as a template, and use Olig(dT) as a reverse transcription primer to perform a reve...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
sizeaaaaaaaaaa
Login to View More

Abstract

The invention discloses a group of gene marker for identifying benign and malignant cases of lung micro nodules and application of the gene marker. The gene marker comprises lung cancer characteristicgenes shown as SEQ ID NO. 1 to SEQ ID NO. 12; the genes are subjected to remarkable differential expression in peripheral blood of micro nodule lung cancer patients and non-lung-cancer patients. Theinvention further discloses application of the gene marker or any combination to preparation of a lung cancer early screening product. The gene marker disclosed by the invention is used for early screening of high-risk lung cancers and has high sensitivity and high specificity; the peripheral blood which is most easily collected clinically is used as a detection sample, a sampling manner is non-invasive and simple and convenient and the detection compliance is high; the gene marker is especially suitable for being matched with imageological diagnosis inspection manners including CT (Computerized Tomography) and the like to screen ultra-early lung cancer of large-scale people, so that the gene marker has a wide application prospect.

Description

technical field [0001] The invention relates to the technical field of molecular biology, in particular to a gene marker for benign and malignant pulmonary micronodules and its use. Background technique [0002] Lung cancer is the leading cause of cancer death in my country's urban population. According to the 2011 statistical yearbook data of the Ministry of Health, the mortality rate of lung cancer in my country in 2010 was 46.46 per 100,000 people, ranking first in the death rate of malignant tumors, almost equivalent to liver cancer, The sum of gastric cancer and colorectal cancer mortality. The prognosis of lung cancer is closely related to the clinical stage at the time of diagnosis. Among them, the treatment effect of ultra-early stage 0 peripheral in situ lung cancer is the best, and the 5-year survival rate of patients after operation is as high as 90%. The survival rate was 61%, while the overall 5-year survival rate of patients with stage II-IV dropped from 34% to...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6886C12N15/11
CPCC12Q1/6886C12Q2600/158
Inventor 杨超马瑞芹
Owner SHANGHAI BIOMEDICAL LAB CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com